STOCK TITAN

Ardent Health (ARDT) Financials

ARDT NYSE
Trailing 12 months to September 30, 2026
Revenue $6.5B +2.0% YoY
Net Income $146.2M -28.7% YoY
EPS (Diluted) $1.03 -30.4% YoY
Operating Cash Flow $481.9M +31.4% YoY
Market Cap $2.6B as of Nov 16, 2026
Price / Sales 0.4x on $6.5B revenue, trailing 12 months to September 30, 2026
Price / Earnings 17.4x on $146.2M net income, trailing 12 months to September 30, 2026
Price / Book 1.8x on $1.4B equity, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 16, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2026, filed Nov 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ARDT SEC filings page.

Ardent Health, Inc. (ARDT) reported $6.5B in revenue over the twelve months to Sep 30, 2026, up 2.0% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI ARDT FY2025

Operating cash flow is strengthening even as profit weakens, revealing earnings volatility beneath continued revenue growth.

FY2025 operating cash flow reached $471M while net income fell to $136M. In FY2024, cash flow was $315M against $210M of profit. This separation means reported earnings are a poor stand-in for near-term cash production: cash conversion strengthened even as accounting profitability weakened.

Revenue grew 6.0% in FY2025, yet net profit margin contracted 1.4 percentage points. At 2.1%, the margin indicates additional sales did not translate proportionally into earnings; net income fell 35.4%, reinforcing that interpretation.

Debt-to-equity declined from 1.7x to 0.8x from FY2023 to FY2025. Equity expanded 92.0% over that span while liabilities reached 68.1% of assets in FY2025, indicating a stronger capital cushion but still substantial creditor financing.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Profitability Growth Leverage Liquidity CashFlow Returns 54 / 100
Financial Health Score (5 of 6 dimensions) 54/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed: here 5 of 6, with the others left out rather than counted as zero. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Ardent Health, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability
53

Profitability ranks operating companies on their operating margin with gains on asset sales taken out, averaged over the last three fiscal years with the newest counting most, and in smaller part on how steady that margin has been. Ardent Health, Inc. scores 53/100 on it among other operating companies.

Growth
60

Growth ranks operating companies on the yearly rate at which revenue compounded across the last three fiscal years (the last two where the earliest reports no revenue), counted in the currency each company reports in so that a move in the exchange rate is not read as growth. Ardent Health, Inc. scores 60/100 on it among other operating companies.

Leverage
43

Ardent Health, Inc. carried $0.84 of long-term debt for every $1 of shareholders' equity at the end of fiscal year 2025, a debt-to-equity ratio of 0.84. With no EBITDA figure for fiscal year 2025, Ardent Health, Inc. is ranked on that ratio rather than on net debt against EBITDA, a lower ratio being the safer one, and scores 43/100 among other operating companies measured the same way.

Liquidity
58

Ardent Health, Inc. held $1.97 of current assets for every $1 of current liabilities at the end of fiscal year 2025, a current ratio of 1.97. Liquidity ranks operating companies on that ratio, and Ardent Health, Inc. scores 58/100 among other operating companies.

Cash Flow
n/a

Not available for Ardent Health, Inc., so it is left out of the overall score, which averages the 5 of 6 dimensions that can be computed.

Returns
58

Returns ranks operating companies on their return on capital employed, which is operating income against total assets less current liabilities, averaged over three fiscal years with the newest weighted most, and in smaller part on how steady that return has been. Ardent Health, Inc. scores 58/100 on it among other operating companies.

Piotroski F-Score Partial
5/8

Ardent Health, Inc. passes 5 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 3 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, the one computable operating efficiency signal (asset turnover improving) does not pass.

Earnings Quality Cash-Backed
3.46x

For every $1 of reported earnings, Ardent Health, Inc. generates $3.46 in operating cash flow ($470.5M OCF vs $135.8M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$1.6B
YoY+3.1%
QoQ+0.2%

Ardent Health, Inc. generated $1.6B in revenue in Q3 2026. This represents an increase of 3.1% from the same quarter a year earlier. Against the prior quarter it is up 0.2%.

Net Income
$44.5M
YoYn/m
QoQ+163.4%

Ardent Health, Inc. reported $44.5M in net income in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. Against the prior quarter it is up 163.4%.

EPS (Diluted)
$0.31
YoYn/m
QoQ+158.3%

Ardent Health, Inc. earned $0.31 per diluted share (EPS) in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. Against the prior quarter it is up 158.3%.

EBITDA

Not reported for Q3 2026.

Cash & Balance Sheet

Cash & Debt
$766.2M
YoY+25.7%
QoQ+5.8%

Ardent Health, Inc. held $766.2M in cash against $1.1B in long-term debt as of Q3 2026.

Shares Outstanding
141M
YoY-1.6%
QoQ-0.1%

Ardent Health, Inc. had 141M shares outstanding in Q3 2026. This represents a decrease of 1.6% from the same quarter a year earlier. Against the prior quarter it is down 0.1%.

Free Cash Flow

Not reported for Q3 2026.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Net Margin
2.7%
YoY+4.2pp
QoQ+1.7pp

Ardent Health, Inc.'s net profit margin was 2.7% in Q3 2026, showing the share of revenue converted to profit. This is up 4.2 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.7 percentage points.

Return on Equity
3.2%
YoY+5.1pp
QoQ+1.9pp

Ardent Health, Inc.'s quarterly ROE was 3.2% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is up 5.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.9 percentage points.

Gross Margin

Not reported for Q3 2026.

Operating Margin

Not reported for Q3 2026.

Capital Allocation

Share Buybacks
$11.0M
YoYn/m

Ardent Health, Inc. spent $11.0M on share buybacks in Q3 2026, returning capital to shareholders by reducing shares outstanding. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.

R&D Spending

Not reported for Q3 2026.

Capital Expenditures

Not reported for Q3 2026.

ARDT Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ARDT quarterly income statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Revenue$1.6B+3.1%$1.6B-1.4%$1.6B+7.0%$1.6B-0.1%$1.6B+8.8%$1.6B+11.9%$1.5B+4.0%$1.6B
SG&A Expenses$42.4M+16.2%$61.2M+87.7%$48.6M+39.3%$36.8M+0.3%$36.5M+8.3%$32.6M+12.0%$34.9M+6.1%$36.7M
Interest Expense$15.3M+10.1%$12.6M-14.7%$12.2M-13.9%$12.4M-8.5%$13.9M-4.9%$14.7M-18.9%$14.2M-26.4%$13.5M
Income Tax$17.6Mn/m$8.5M-67.6%$16.1M+5.7%$18.1M-31.3%-$3.4M-130.8%$26.3M+72.7%$15.2M+42.2%$26.4M
Net Income$44.5Mn/m$16.9M-76.8%$39.9M-3.7%$45.0M-60.6%-$23.5M-189.2%$73.0M+70.6%$41.4M+53.0%$114.2Mn/m
EPS (Basic)$0.32n/m$0.12-76.9%$0.28-6.7%$0.31-63.5%-$0.17-189.5%$0.52+52.9%$0.30+42.9%$0.85n/m
EPS (Diluted)$0.31n/m$0.12-76.9%$0.28-3.4%$0.32-61.9%-$0.17-189.5%$0.52+52.9%$0.29+38.1%$0.84n/m
Diluted Shares (Avg)142M+0.3%143M+1.1%142M+0.8%N/A141M+2.7%142M+12.2%141M+11.6%N/A

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, R&D Expenses, Operating Income, EBITDA.

ARDT Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ARDT quarterly balance sheet
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Total Assets$5.4B+3.9%$5.3B+5.0%$5.3B+7.0%$5.3B+6.7%$5.2B+7.4%$5.0B+9.1%$4.9B$5.0B+4.7%
Current Assets$2.2B+10.9%$2.1B+9.5%$2.0B+14.7%$2.1B+12.3%$2.0B+15.8%$1.9B+25.0%$1.8B$1.8B+13.3%
Cash & Equivalents$766.2M+25.7%$724.5M+34.0%$609.7M+23.2%$709.6M+27.4%$609.4M+8.2%$540.6M+61.6%$495.0M+32.8%$556.8M+27.2%
Short-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Inventory$110.1M-9.5%$116.0M-2.0%$119.8M-0.4%$118.6M+3.0%$121.6M+12.3%$118.4M+12.8%$120.4M$115.1M+9.1%
Accounts Receivable$661.8M-9.3%$696.0M-8.3%$686.0M-11.7%$686.1M-7.7%$729.4M+3.4%$758.6M+5.2%$776.5M$743.0M-4.2%
Long-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Goodwill$861.9M-1.8%$879.3M+0.2%$879.3M+0.3%$879.5M+3.2%$877.5M+3.0%$877.7M+3.0%$876.6M$852.1M+0.9%
Total Liabilities$3.6B+1.4%$3.5B+4.7%$3.5B+5.2%$3.6B+5.0%$3.5B+3.2%$3.4B-1.9%$3.3B$3.4B-5.9%
Current Liabilities$1.0B+7.9%$976.3M+10.8%$951.5M+14.6%$1.0B+10.7%$943.2M+6.3%$880.9M-3.0%$830.1M$945.4M-4.9%
Non-Current Liabilities$2.6B-1.0%$2.6B+2.5%$2.6B+2.1%$2.6B+2.8%$2.6B+2.1%$2.5B-1.5%$2.5B$2.5B-6.3%
Long-Term Debt$1.1B-1.6%$1.1B-1.6%$1.1B-1.6%$1.1B-0.9%$1.1B+0.3%$1.1B+0.8%$1.1B$1.1B-7.1%
Total Equity$1.4B+12.8%$1.4B+7.6%$1.3B+13.8%$1.3B+13.8%$1.2B+23.1%$1.3B+69.6%$1.2B$1.1B+68.6%
Retained Earnings$602.9M+32.0%$558.4M+16.3%$541.5M+33.0%$501.6M+37.1%$456.7M+81.5%$480.1M+113.1%$407.2M$365.8M+135.3%

ARDT Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ARDT quarterly cash flow statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Cash Flow$121.9M-21.0%$196.7M+67.4%-$60.2Mn/m$223.4M+86.9%$154.4M+72.1%$117.5M-2.4%-$24.8Mn/m$119.6M+77.1%
Depreciation & Amortization$41.1M+4.9%$41.3M+5.2%$43.0M+18.7%$41.0M+8.4%$39.2M+6.5%$39.3M+8.3%$36.2M+2.4%$37.9M+5.2%
Investing Cash Flow-$40.1Mn/m-$39.2Mn/m-$27.9Mn/m-$86.2Mn/m-$58.6Mn/m-$46.2Mn/m-$23.1Mn/m-$105.4Mn/m
Financing Cash Flow-$40.0Mn/m-$42.8Mn/m-$11.8Mn/m-$37.0Mn/m-$26.9M-114.7%-$25.7Mn/m-$13.8Mn/m-$20.5Mn/m
Share Buybacks$11.0Mn/mN/AN/AN/A$0N/AN/AN/A

Not reported in any period shown, so not listed: Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Dividends Paid.

ARDT Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ARDT quarterly financial ratios
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Net Margin2.7%+4.2pp1.0%-3.4pp2.5%-0.3pp2.8%-4.3pp-1.5%-3.3pp4.4%+1.5pp2.8%+0.9pp7.1%
Return on Equity3.2%+5.1pp1.3%-4.6pp3.0%-0.5pp3.5%-6.6pp-1.9%-4.5pp5.8%0.0pp3.5%10.1%+10.7pp
Return on Assets0.8%+1.3pp0.3%-1.1pp0.8%-0.1pp0.9%-1.4pp-0.5%-1.0pp1.5%+0.5pp0.8%2.3%+2.4pp
Current Ratio2.13+0.1x2.100.0x2.120.0x1.970.0x2.08+0.2x2.13+0.5x2.121.94+0.3x
Debt-to-Equity0.77-0.1x0.79-0.1x0.80-0.1x0.84-0.1x0.88-0.2x0.87-0.6x0.930.96-0.8x
Liabilities-to-Equity2.56-0.3x2.62-0.1x2.63-0.2x2.80-0.2x2.84-0.5x2.69-2.0x2.853.04-2.4x
Asset Turnover0.300.0x0.310.0x0.310.0x0.300.0x0.310.0x0.330.0x0.300.32

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Ardent Health, Inc. ARDT FY2025 $6.3B $135.8M 2.1% $2.6B 54/100
Pediatrix Medical Group, Inc. MD FY2025 $1.9B $165.4M 8.6% $2.5B 44/100
Brookdale Senior Living, Inc. BKD FY2025 $3.2B -$262.7M -8.2% $2.1B 24/100
Acadia Healthcare Company, Inc. ACHC FY2025 $3.3B -$1.1B -33.3% $3.6B 27/100
Aveanna Healthcare Holdings Inc. AVAH FY2026 $2.4B $225.0M 9.3% $2.5B 44/100
Addus HomeCare Corp. ADUS FY2025 $1.4B $95.9M 6.7% $2.3B 68/100

Frequently Asked Questions

Ardent Health, Inc. (ARDT) reported $6.3B in total revenue for fiscal year 2025. This represents a 6.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Ardent Health, Inc. (ARDT) revenue grew by 6.0% year-over-year, from $6.0B to $6.3B in fiscal year 2025.

Yes, Ardent Health, Inc. (ARDT) reported a net income of $146.2M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net income of $135.8M, with a net profit margin of 2.1%.

Ardent Health, Inc. (ARDT) reported diluted earnings per share of $0.96 for fiscal year 2025. This represents a -39.2% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

As of fiscal year 2025, Ardent Health, Inc. (ARDT) had $709.6M in cash and equivalents against $1.1B in long-term debt.

Ardent Health, Inc. (ARDT) had a net profit margin of 2.1% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Ardent Health, Inc. (ARDT) has a return on equity of 10.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Ardent Health, Inc. (ARDT) generated $470.5M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

Ardent Health, Inc. (ARDT) had $5.3B in total assets as of fiscal year 2025, including both current and long-term assets.

Ardent Health, Inc. (ARDT) had 143M shares outstanding as of fiscal year 2025.

Ardent Health, Inc. (ARDT) had a current ratio of 1.97 as of fiscal year 2025, which is generally considered healthy.

Ardent Health, Inc. (ARDT) had a debt-to-equity ratio of 0.84 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.

Ardent Health, Inc. (ARDT) had a liabilities-to-equity ratio of 2.80 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.

Ardent Health, Inc. (ARDT) had a return on assets of 2.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Ardent Health, Inc. (ARDT) trades at 17.4x earnings, its market capitalization divided by $146.2M net income, trailing 12 months to September 30, 2026. The market capitalization is $2.6B as of Nov 16, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Ardent Health, Inc. (ARDT) trades at 0.4x sales, its market capitalization divided by $6.5B revenue, trailing 12 months to September 30, 2026. The market capitalization is $2.6B as of Nov 16, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Ardent Health, Inc. (ARDT) has a Piotroski F-Score of 5 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Ardent Health, Inc. (ARDT) has an earnings quality ratio of 3.46x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Ardent Health, Inc. (ARDT) scores 54 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. For Ardent Health, Inc. it averages the 5 of 6 dimensions that can be computed; the others are left out rather than counted as zero. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.

Back to top